Upstream Bio to Unveil New Verekitug Data in CRSwNP at AAAAI 2026
Event summary
- Upstream Bio will present additional Phase 2 VIBRANT trial data on verekitug for CRSwNP at AAAAI 2026 on March 1, 2026.
- New analyses assess efficacy with adjustment for concomitant rescue therapy use.
- Verekitug is a novel TSLP receptor antagonist, the only one in clinical development.
- Upstream Bio has three ongoing Phase 2 trials for verekitug across CRSwNP, severe asthma, and COPD.
The big picture
Upstream Bio's presentation at AAAAI 2026 highlights the growing interest in TSLP pathway inhibition for respiratory diseases. The company is positioning verekitug as a potential first-in-class therapy, competing with other emerging treatments targeting the inflammatory cascade. Success in CRSwNP could validate the broader strategy of leveraging a single mechanism across multiple severe respiratory conditions.
What we're watching
- Clinical Validation
- How the additional VIBRANT trial data will impact verekitug's clinical profile and differentiation in CRSwNP.
- Regulatory Pathway
- Whether positive data could accelerate verekitug's development timeline for CRSwNP and other indications.
- Market Opportunity
- The pace at which Upstream Bio can expand verekitug's potential into multiple severe respiratory diseases.
Related topics